Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839876 | 0.83 | KDM4C (0.46) | KDM4C | |
| SCHEMBL3585235 | 0.81 | KDM4C (0.54) | KDM4CNR3C1 | |
| SCHEMBL7776691 | 0.81 | ESR1 (0.53) | SIGMAR1 | |
| SCHEMBL29673168 | 0.81 | HTR2A (0.38) | KDM4C | |
| SCHEMBL24542984 | 0.81 | HTR2A (0.38) | KDM4C | |
| SCHEMBL22905344 | 0.80 | KDM4C (0.52) | KDM4CNR3C1SIGMAR1 | |
| SCHEMBL2422836 | 0.77 | UGT2B17 (0.47) | KDM4C | |
| SCHEMBL8811492 | 0.76 | SIGMAR1 (0.57) | SIGMAR1HTR1A | |
| SCHEMBL8019430 | 0.76 | SIGMAR1 (0.57) | SIGMAR1HTR1A | |
| Hydrochloric Acid SCHEMBL9521256 | 0.76 | KDM4C (0.49) | KDM4CNR3C1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3436445-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174003-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | KDM4C 14/4885NR3C1 2049/4885KDM2B 15/4885 |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 14/4885NR3C1 2049/4885KDM2B 15/4885 |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 14/4885NR3C1 2049/4885KDM2B 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.